KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Assets (2016 - 2026)

Emergent BioSolutions has reported Assets over the past 17 years, most recently at $1.3 billion for Q1 2026.

  • For Q1 2026, Assets fell 7.41% year-over-year to $1.3 billion; the TTM value through Mar 2026 reached $1.3 billion, down 7.41%, while the annual FY2025 figure was $1.3 billion, 5.12% down from the prior year.
  • Assets for Q1 2026 was $1.3 billion at Emergent BioSolutions, roughly flat from $1.3 billion in the prior quarter.
  • Over five years, Assets peaked at $3.2 billion in Q4 2022 and troughed at $1.3 billion in Q4 2025.
  • A 5-year average of $2.0 billion and a median of $1.8 billion in 2024 define the central range for Assets.
  • Biggest five-year swings in Assets: increased 7.05% in 2022 and later plummeted 42.42% in 2023.
  • Year by year, Assets stood at $3.2 billion in 2022, then plummeted by 42.42% to $1.8 billion in 2023, then decreased by 23.78% to $1.4 billion in 2024, then dropped by 5.12% to $1.3 billion in 2025, then grew by 0.14% to $1.3 billion in 2026.
  • Business Quant data shows Assets for EBS at $1.3 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.5 billion in Q3 2025.